Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Panniculitis | 1 | 2024 | 4 | 0.880 |
Why?
|
| Arthritis | 1 | 2024 | 53 | 0.850 |
Why?
|
| Pancreatitis | 1 | 2024 | 97 | 0.820 |
Why?
|
| Parenteral Nutrition, Home | 3 | 2023 | 3 | 0.790 |
Why?
|
| Short Bowel Syndrome | 2 | 2023 | 5 | 0.600 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2012 | 28 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2004 | 34 | 0.410 |
Why?
|
| Fish Oils | 1 | 2012 | 43 | 0.370 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2012 | 37 | 0.370 |
Why?
|
| Dietary Fats | 1 | 2012 | 174 | 0.360 |
Why?
|
| Nutritional Requirements | 1 | 2011 | 20 | 0.350 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 8 | 0.350 |
Why?
|
| Dietary Proteins | 1 | 2011 | 42 | 0.350 |
Why?
|
| Liver Diseases | 1 | 2012 | 156 | 0.340 |
Why?
|
| Fatty Liver | 1 | 2011 | 108 | 0.340 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 219 | 0.320 |
Why?
|
| Oxidative Stress | 1 | 2011 | 298 | 0.310 |
Why?
|
| Liver | 1 | 2011 | 855 | 0.260 |
Why?
|
| Inflammation | 1 | 2011 | 1147 | 0.230 |
Why?
|
| Hypophosphatemia | 1 | 2004 | 7 | 0.220 |
Why?
|
| Living Donors | 1 | 2004 | 77 | 0.220 |
Why?
|
| Phosphates | 1 | 2004 | 93 | 0.210 |
Why?
|
| Obesity | 1 | 2011 | 1234 | 0.210 |
Why?
|
| Liver Transplantation | 2 | 2007 | 216 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 47 | 0.180 |
Why?
|
| Acclimatization | 1 | 2021 | 11 | 0.180 |
Why?
|
| Altitude | 1 | 2021 | 15 | 0.180 |
Why?
|
| Cross Infection | 1 | 2002 | 164 | 0.170 |
Why?
|
| Alcoholism | 1 | 2024 | 318 | 0.170 |
Why?
|
| HIV Infections | 2 | 2018 | 969 | 0.170 |
Why?
|
| Middle Aged | 8 | 2024 | 17609 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Neuromuscular Junction | 1 | 2019 | 77 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.150 |
Why?
|
| Myosins | 1 | 2019 | 114 | 0.140 |
Why?
|
| Humans | 15 | 2024 | 63467 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 154 | 0.130 |
Why?
|
| Zebrafish | 1 | 2019 | 347 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 24 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 76 | 0.120 |
Why?
|
| Sexual Partners | 1 | 2016 | 76 | 0.120 |
Why?
|
| Naloxone | 1 | 2014 | 60 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 53 | 0.110 |
Why?
|
| Male | 8 | 2024 | 29906 | 0.100 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 136 | 0.100 |
Why?
|
| Soybean Oil | 1 | 2012 | 32 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 38 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Opiate Substitution Treatment | 1 | 2014 | 206 | 0.090 |
Why?
|
| Diet, Protein-Restricted | 1 | 2011 | 12 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 298 | 0.090 |
Why?
|
| Buprenorphine | 1 | 2014 | 192 | 0.090 |
Why?
|
| HIV-1 | 1 | 2016 | 721 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2011 | 90 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2011 | 218 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 379 | 0.080 |
Why?
|
| Sleep | 2 | 2023 | 225 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 536 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 462 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2007 | 34 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2007 | 31 | 0.070 |
Why?
|
| Female | 7 | 2023 | 32889 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 771 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2014 | 507 | 0.070 |
Why?
|
| Postgastrectomy Syndromes | 1 | 2006 | 4 | 0.060 |
Why?
|
| Trace Elements | 1 | 2006 | 21 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2007 | 200 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2006 | 40 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 51 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 173 | 0.060 |
Why?
|
| Anion Exchange Resins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2004 | 138 | 0.050 |
Why?
|
| Probiotics | 1 | 2004 | 46 | 0.050 |
Why?
|
| United States | 2 | 2018 | 7842 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2004 | 164 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 150 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 739 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2018 | 5685 | 0.050 |
Why?
|
| Adult | 4 | 2023 | 16830 | 0.050 |
Why?
|
| Hypocapnia | 1 | 2021 | 1 | 0.040 |
Why?
|
| Bicarbonates | 1 | 2021 | 16 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2006 | 1309 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 641 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 467 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1008 | 0.040 |
Why?
|
| Hypoxia | 1 | 2021 | 115 | 0.040 |
Why?
|
| Malawi | 1 | 2018 | 11 | 0.040 |
Why?
|
| South Africa | 1 | 2018 | 14 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 72 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 100 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 186 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2018 | 121 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 114 | 0.040 |
Why?
|
| Young Adult | 2 | 2018 | 4696 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 19 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 84 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 377 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 422 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1228 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 18 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 39 | 0.030 |
Why?
|
| Thailand | 1 | 2014 | 98 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2679 | 0.030 |
Why?
|
| China | 1 | 2014 | 164 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 2081 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2462 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5356 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2007 | 4 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2007 | 16 | 0.020 |
Why?
|
| Etanercept | 1 | 2007 | 32 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 63 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 14443 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 6253 | 0.020 |
Why?
|
| Phospholipids | 1 | 2007 | 82 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2006 | 3 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 166 | 0.020 |
Why?
|
| Ataxia | 1 | 2006 | 23 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 28 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2007 | 321 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 244 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 39 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 459 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 234 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 615 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 20664 | 0.010 |
Why?
|